With the release of the World Health Organization's guideline on GLP 1 medications for obesity management, policymakers and clinicians are increasingly asking what global eligibility for these therapies looks like in practice. Co authored CagriSema, Novo Nordisk's Latest Obesity Drug Offering, Disappoints Investors with Trial Results Xtalks You thought Ozempic was big? Just wait. The next generation of weight loss medications is already in clinical trials oral pills, monthly injections, and even triple action drugs that may work better than Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis Annals of Saudi Medicine Bulk Tirzepatide Available At Affordable Prices Online Now